MTPH.L Share News (MTPH)

IN BRIEF: Midatech Pharma delisting and name change approved

Midatech Pharma PLC - Cardiff-based R&D biotechnology company focused on improving the bio-delivery and bio-distribution of medicines - Says resolutions put forward at general meeting, including name change, share consolidation and cancellation of AIM listing, approved. Under the consolidation, every 20 shares will be consolidated into one new ordinary share. Adds that ratio of American depositary shares will change to one ADS per five shares, from one ADS per 25 shares previously. Name change to Biodexa Pharmaceuticals PLC, effective on Monday, also approved. Listing of shares on AIM is expected to be cancelled a month from now. Its sole listing will be on Nasdaq.

UK shareholder meetings calendar - next 7 days

Midatech Pharma shares up as closed USD6.0 million private placement

(Alliance News) - Midatech Pharma PLC on Wednesday said it has raised USD6.0 million through a private placement of 10.3 million shares at USD0.58 each.

IN BRIEF: Midatech Pharma raises USD6.0 million for clinical asset

Midatech Pharma PLC - Cardiff-based R&D biotechnology company focused on improving the bio-delivery and bio-distribution of medicines - Raises gross proceeds of around USD6.0 million through the issue of 10.3 million units at an issue price of USD0.58 per unit. One unit either includes one American depository share, one A warrant and one and one-half B warrant, or one pre-funded warrant, one A warrant and one and one-half B warrant. Says that the net proceeds will enable the company to focus on developing MTX110, its clinical asset, and provide it with sufficient working capital until December 2023.

Midatech's Nasdaq price falls below minimum of USD1.00 per share

(Alliance News) - Midatech Pharma PLC on Friday said it received notice that its share price has fallen short of the minimum needed according to Nasdaq Stock Market LLC rules.

UK shareholder meetings calendar - next 7 days

TRADING UPDATES: Alliance Pharma hires COO; Empire advances field work

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Gulf Keystone chair to retire; JZ Capital cashes in

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

AIM WINNERS & LOSERS: Midatech shares soar on Bioasis acquisition

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Midatech Pharma recruits first patient study of MTX110 in glioblastoma

(Alliance News) - Midatech Pharma Plc announced on Monday it enrolled the first patient into its Phase 1 study of MTX110 for the treatment of recurrent glioblastoma at the Preston Robert Tisch Brain Tumor Center at Duke University in the US.

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

TRADING UPDATES: Chaarat enters takeover discussions with Shanta Gold

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

TRADING UPDATES: Epwin lifts interim payout; Anpario profit falls

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

AIM WINNERS & LOSERS: K3 Capital upbeat; Morses sinks after warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

IN BRIEF: Midatech Pharma gets Orphan Medicinal Product designation

Midatech Pharma PLC - Cardiff-based biotechnology company focused on improving the bio-delivery and biodistribution of medicines - Receives Orphan Medicinal Product designation from the European Medicines Agency for the development programme for MTX110. Explains that the designation offers protocol development assistance, a reduction in fees and market exclusivity upon the successful approval of the drug.